1 Masaki T,Yanagisawa M,Goto K.Phy siology and pharmacology of endothelins[J].Med Res Rev,1992;12:391-421 2 杨小东,陈文彬,陈俊杰.内皮素在低氧性肺动脉高压大鼠肺内表达和水平变化的研究[J].中华内科杂志,1996;35:734-7 3 陈文彬,程德云.肺心病患者血浆内皮素-1 水平的变化及卡托普利对其的影响[J].华西医科大学学报,1999;30:179-81 4 Riechers H,Albrecht HP,Amberg W,Baumann E,Bernard H,Bohm HJ,et al.Discovery and optimization of a novel class of orally active nonpepitide endothelin-A receptor antagonists[J].J Med Chem,1996;39:2123-8 5 Witte K,Reitenbach I,Stolpe K,Schiling L,Kirchengast M,Lemmer B.Effects of the endothelin A receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats[J].J Cardiovasc Pharmacol,2003;41:890-6 6 Schirger JA,Chen HH,Jougasaki M,Lisy O,Boerrigter G,Cataliotti A,Burnett JC.Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention[J].Circulation,2004;109:249 7 Sorbera LA,Silvestre J,Castaner J.LU135252[J].Drugs Future,1999;24:141 8 薛全福,胡长贵.常压缺氧性大鼠肺动脉高压模型的建立[J].中华结核和呼吸杂志,1989;12:350-2 9 Runo JR,Loyd JE.Primary pulmonary hypertension[J].Lancet,2003;361:1533-44 10 Rubin L,Badesch DB,Barst RJ,Galie N,Black CM,Keogh A,et al.Bosentan therapy for pulmonary arterial hypertention[J].N Engl JMed,2002;346:896-903 11 Hom EM,Widlitz AC,Barst RJ.Sitaxsentan,a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension[J].Expert Opin Investig Drugs,2004;13:1483-92 12 Galie N,Badesch D,Oudiz R,Simonneau G,Mcgood MD,Keogh AM.Ambrisentan Therapy for Pulmonary Arterial Hyper-tension[J].J Am Coll Cardiol,2005;46:529-35 13 Jasmin JF,Cernacek P,Dupuis J.Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension:response to chronic ETA receptor blockade[J].Clin Sci,2003;105:647-53 |